Jove
Visualize
Contact Us

Related Experiment Videos

HER-2/neu (erbB-2) and the cell cycle.

D Busse1, R S Doughty, C L Arteaga

  • 1Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

Seminars in Oncology
|March 10, 2001
PubMed
Summary

HER-2 proto-oncogene signaling activates pathways affecting cell cycle regulators, potentially driving cancer. Targeting HER-2 may require reversing these effects, with cyclin D1 and p27KIP1 implicated in cell cycle disruption.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: PIK3CA<sup>H1047R</sup>- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.

Oncogene·2025
Same author

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients.

Antimicrobial agents and chemotherapy·2022
Same author

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.

NPJ precision oncology·2022
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • HER-2 proto-oncogene amplification and overexpression are linked to various cancers.
  • HER-2 signaling influences cell cycle progression, contributing to cellular transformation.
  • Therapeutic strategies targeting HER-2 require understanding its impact on cell cycle regulation.

Purpose of the Study:

  • To investigate the role of HER-2 signaling in modulating cell cycle regulators.
  • To identify specific molecules involved in HER-2-mediated cell cycle subversion.
  • To explore potential mechanisms for reversing HER-2 effects for therapeutic benefit.

Main Methods:

  • Analysis of signaling pathways activated by HER-2.
  • Examination of the expression and function of cell cycle regulators.
  • Investigation of the involvement of cyclin D1 and p27KIP1 in HER-2 signaling.

Main Results:

  • HER-2 signaling activates biochemical pathways that alter cell cycle regulators.
  • These alterations are critical for the transformed phenotype associated with HER-2.
  • Cyclin D1 and p27KIP1 appear to be involved in disrupting the G1/S cell cycle transition via HER-2 pathways.

Conclusions:

  • HER-2 signaling profoundly impacts cell cycle control, promoting cancer phenotypes.
  • Understanding these molecular alterations is crucial for effective HER-2 targeted therapies.
  • Cyclin D1 and p27KIP1 are key players in HER-2-driven cell cycle dysregulation.

Related Experiment Videos